Bridger Management LLC Purchases 4,160 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bridger Management LLC raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,182 shares of the biopharmaceutical company's stock after purchasing an additional 4,160 shares during the quarter. Alnylam Pharmaceuticals accounts for 5.2% of Bridger Management LLC's portfolio, making the stock its 7th largest holding. Bridger Management LLC's holdings in Alnylam Pharmaceuticals were worth $9,691,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ALNY. Larson Financial Group LLC lifted its holdings in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. OFI Invest Asset Management bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $35,000. Versant Capital Management Inc boosted its holdings in shares of Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares in the last quarter. Finally, IFP Advisors Inc grew its position in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ ALNY traded down $6.35 during mid-day trading on Friday, reaching $252.00. 656,363 shares of the company's stock were exchanged, compared to its average volume of 901,288. The business has a fifty day simple moving average of $250.53 and a 200 day simple moving average of $254.26. Alnylam Pharmaceuticals, Inc. has a twelve month low of $144.73 and a twelve month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $32.86 billion, a price-to-earnings ratio of -116.13 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The company's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.16) earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of recent analyst reports. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. UBS Group raised their price objective on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Chardan Capital upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, StockNews.com raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $319.17.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,392 shares of company stock valued at $1,875,627 over the last three months. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.